Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study.

In this first pilot study including kidney allograft recipients with early dnDSA, preemptive treatment with high-dose IVIG alone did not prevent acute ABMR and had minimal effects on DSA outcome and B cell phenotype.